سعر تيجاستيرك 50مجم فيال وريد 2026

Tigecycline 50 mg powder for intravenous infusion, 1 vial, by Hikma (Egypt); glycylcycline (tetracycline-class) antibacterial.

• Complicated skin and skin structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia caused by susceptible bacteria (adults 18 years and older); not indicated for diabetic foot infection or hospital-acquired/ventilator-associated pneumonia.Population: Adults 18 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in clinical trials: nausea (26%), vomiting (18%), diarrhea (12%), infection, abdominal pain, headache and increased SGPT.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to tigecycline or any excipient (anaphylactic reactions reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased all-cause mortality versus comparators in a meta-analysis (risk difference 0.6%); reserve for situations when alternative treatments are not suitable.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Anaphylaxis (avoid in known tetracycline hypersensitivity), hepatic adverse effects, pancreatitis (including fatal cases), hypofibrinogenemia, tooth discoloration/enamel hypoplasia and reversible inhibition of bone growth when used during tooth development, and C. difficile-associated diarrhea.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Like other tetracycline-class drugs, may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when given in the second and third trimesters; no human data on major birth defects or miscarriage; animal studies showed reduced fetal weight and delayed ossification.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; tetracycline-class drugs are present in breast milk; low oral bioavailability means infant exposure is expected to be low.International label, same formulation · DailyMed (U.S. National Library of Medicine)